A slew of recent mergers and acquisitions in the brand-name pharmaceutical industry, with more expected to come, highlights the changing dynamic in drug development, as companies realign their business strategies to better reflect the competitive environment and focus on differentiated products for which payers are willing to pay a premium, key industry analysts say. The market shift comes as Congress seeks to speed drug innovation by reforming FDA and boosting NIH, and the pharmaceutical industry simultaneously faces growing criticism over...
You've followed a link to an article or document on InsideHealthPolicy.com.
There are two ways you can access this content.
Subscriber Login
If you are an InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:
Take A Trial Subscription
If you haven't already had a trial subscription to InsideHealthPolicy.com, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.
Sign up for a trial subscription.